Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Campaign raises awareness about importance of dog vaccination

In recognition of World Rabies Day on September 28, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the launch of a global campaign to raise awareness among veterinarians, dog owners and volunteers who are committed to eliminate rabies through ongoing dog vaccination efforts. In partnership with Mission Rabies and Rabies Free Africa, the social media initiative recognizes and celebrates those individuals who are committed to protecting and saving canine as well as human lives, using the hashtag, #ForThemForUs.

"Many of us love and rely on our dogs, who in many cases are not only much-loved family members, but also hard-working companions," said Luke Gamble, BVSc, DVM&S, FRCVS, founder, Mission Rabies. "On this World Rabies Day, we want to recognize the invaluable role dogs play in our lives. When we protect our dogs from rabies, we are also protecting ourselves from this deadly disease. Showcasing those efforts through #ForThemForUs moments is a fitting way to raise awareness about why vaccinating dogs and educating people about preventing rabies matters and saves lives."

Around the world, there are an estimated 900 million dogs i but the majority (75-85%) are not household pets ii . In order to prevent rabies transmission in rabies-endemic areas, at least 70% of the dogs there need to be protected through annual mass-vaccination iii . For over 20 years, Merck Animal Health, through the Afya Program, has been dedicated to rabies prevention and has donated over three million doses of rabies vaccine to help meet the World Health Organization (WHO) "Zero by 2030" goal.

Each year, an estimated 59,000 people die from rabies, with over 99% of cases contracted from a dog bite. Additionally, 40% of those deaths occur in children 15 years and under. This is in part because of low rates of canine vaccination in rabies endemic areas and a lack of awareness about the disease.

"With Merck Animal Health, we have made significant progress on the research needed to design cost-effective and efficient vaccination programs that reduce rates of rabies in both dogs and humans," notes Felix Lankester, DVM, Ph.D., director, Rabies Free Africa, Paul G. Allen School for Global Animal Health, Washington State University. "From scientific research to actual vaccination programs, we are refining the tools we need to prevent rabies. While doing so, we must continue to work together with local governments and healthcare organizations supporting local communities as they continue rabies prevention where it is most needed. This will help us achieve our 2030 rabies elimination goal."

Collaboration must continue among human, animal and environmental health organizations to advance sustainable rabies prevention efforts, including annual mass-vaccination. Through this One Health approach, local, regional, national and global animal health advocates all have a critical role in addressing this public health threat and must work together to keep both dogs and humans healthy.

"Experiencing first-hand the important work of our partners, veterinarians and volunteers was the inspiration behind our campaign, #ForThemForUs," said Ingrid Deuzeman, global marketing director, Companion Animal Vaccines, Merck Animal Health. "We wanted to recognize the global community for their role in eliminating rabies – from the local veterinarian who vaccinates dogs in a veterinary clinic to the door-to-door efforts of volunteers and the Mission Rabies and Rabies Free Africa teams across the African continent and beyond to vaccinate owned and stray dogs. We hope that by everyone sharing their #ForThemForUs moments with the world, these outstanding individuals and not-for-profit organizations will gain even more awareness and support to expand rabies prevention and elimination efforts."

For example, as a commitment to rabies vaccination in Goa, India, there have been no recorded human rabies deaths for two years. "During the COVID-19 pandemic, the Mission Rabies local team remained essential to ensure rabies did not re-emerge in the area. Throughout this period, our team was on-call to respond to any reported rabid dogs. After several positive cases were confirmed, they also quickly launched an emergency rabies vaccination drive to prevent spread," said Gamble.

Veterinarians, dog owners and volunteers are invited to share photos and videos of their inspirational work in keeping dogs rabies-free, using the hashtag, #ForThemForUs.

About Mission Rabies

Mission Rabies was initially founded as an initiative by Worldwide Veterinary Service (WVS), a United Kingdom-based charity group that assists animals. Mission Rabies has a One Health approach driven by research to eliminate dog bite transmitted rabies (a disease that is estimated to kill 59,000 people annually). Launched in September 2013 with a mission to vaccinate 50,000 dogs against rabies across India, Mission Rabies teams have since then vaccinated 1.1 million dogs and educated more than three million children in dog bite prevention in rabies endemic countries. For more information, visit www.missionrabies.com .

About Rabies Free Africa

Rabies Free Africa is empowering countries in east Africa to create self-sustaining programs to eliminate current human rabies deaths and set up surveillance systems to identify future outbreaks for containment. To reach the global goal by 2030, the focus needs to be on decreasing the cost of vaccinating dogs and increasing access to vaccines. Rabies Free Africa continues its work to discover ways to decrease the cost of mass-dog vaccinations and refine country and continent-wide programs that make the best use of limited resources. For more information, visit www.globalhealth.wsu.edu/initiatives/rabies-free-africa/ .

About the Afya Program

The Afya Program comprises a number of rabies control projects supported by Merck Animal Health rabies vaccine donations, including Rabies Free Africa, Mission Rabies and The Sharon Live On Project. These projects have been brought together under the name "Afya," which means "health" in Swahili. The Afya Program is committed to supporting the Zero by 30 Initiative, with the goal of eliminating rabies by 2030. For more information, visit www.afya.org .

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The   Science of Healthier Animals® , Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn , Facebook , and Twitter at @MerckAH.

i World Atlas. How Many Dogs Are There In The World? Accessed June 15, 2020. https://www.worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html

ii World Atlas. How Many Dogs Are There In The World? Accessed June 15, 2020. https://www.worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html

iii The World Health Organization. Frequently Asked Questions about Rabies for the General Public . Accessed June 15, 2020. https://www.who.int/rabies/Rabies_General_Public_FAQs_Sep2018.pdf?ua=1

Merck
Media Contact:
Michael Close
+ 1 (267) 305-1211
Michael.L.Close@merck.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing -
  - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -
  - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -
  - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -
  - PTC will host a conference call on Dec. 2, 2024 , at 8:30 am EST -

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio to receive upfront, and potential milestones and tiered royalty payments

Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Pill spelling "big pharma."

Big Pharma Stocks Eli Lilly, AbbVie and Pfizer Share Q3 Results

Major pharmaceutical players Eli Lilly (NYSE:LLY), AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) reported mixed Q3 results, with each company facing distinct market forces, ranging from supply issues to financial constraints.

In its latest quarterly report, released on Wednesday (October 30), Eli Lilly missed on sales expectations for Zepbound, its popular weight-loss drug, and Mounjaro, its diabetes medication. Despite growing US demand for these products, supply chain management issues impacted the company’s ability to meet Wall Street's expectations.

According to Reuters, Eli Lilly dropped 8 percent on the news, reducing its market valuation by nearly US$70 billion.

Keep reading...Show less
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical company is diverse and dynamic.

Canadian pharma companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Here the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXV and CSE by year-to-date gains. All data was compiled on October 28, 2024, using TradingView’s stock screener, and the companies considered had market caps above C$10 million at that time. Read on to learn about what's been driving their share prices.

Keep reading...Show less

Latest Press Releases

Related News

×